UCL Study Probes Blood-Brain Barrier Leakage in Glioma-Related Epilepsy
A prospective case-control study from University College London will examine whether blood-brain barrier dysfunction tracks with glioma, tumor-related epilepsy, and structural brain change. The protocol, registered as NCT07909460, is built around a clinically intuitive question with real diagnostic consequences: does abnormal barrier leakage help explain why some gliomas provoke seizures while others do not?
The study centers on a recently developed imaging approach called filter exchange imaging, which is intended to quantify subtle barrier leakage rather than rely only on the coarse signal changes seen on conventional contrast MRI. In glioma, that distinction is biologically important. The blood-brain barrier is supposed to restrict the passage of circulating substances into brain tissue; once that barrier becomes leaky, inflammatory mediators, edema-related changes, and tumor-associated tissue injury can alter neuronal excitability and local network behavior. In practical terms, a tumor that destabilizes the barrier may be more likely to create an epileptogenic environment.
Why Barrier Leakage Could Matter for Seizure Biology
Gliomas are already known to be among the most common and aggressive primary brain tumors in children and adults. A large share of patients with glioma develop epilepsy, and the seizures are often difficult to control. The mechanistic bridge between the tumor and the seizure focus remains incomplete, but the current protocol is designed around two linked hypotheses: inflammation and shared disease pathways may connect the two conditions, and seizure-related electrical activity may in turn promote tumor growth and spread.
One sentence captures the clinical stakes plainly: tumor-associated seizures may reflect more than mass effect or location alone.
By comparing people with glioma and epilepsy, people with glioma without epilepsy, and healthy controls, the study aims to isolate whether barrier leakage is tied specifically to epileptogenesis rather than glioma presence alone. That separation matters because frontal and temporal tumors can present very differently at the bedside even when they arise within the same broad disease category. If leakage is greater in the epilepsy group, the imaging marker may eventually serve as a biologically anchored readout of seizure susceptibility in brain tumor patients.
A Three-Group Design Built Around Adult Frontal and Temporal Gliomas
The planned cohort includes 56 participants in total. Nineteen will have glioma with epilepsy, 19 will have glioma without epilepsy, and 18 will serve as healthy controls without glioma or epilepsy. Adults between 18 and 65 years are eligible, and the study population is limited to gliomas located in the frontal or temporal regions of the brain. Those anatomic constraints make sense: both regions are strongly implicated in seizure generation, and focusing there should reduce noise from highly variable tumor locations.
Eligibility criteria are fairly strict. Participants must be able to provide informed consent, and those in the epilepsy cohort must have confirmed glioma-related epilepsy. Controls cannot have a history of glioma or epilepsy. The protocol also excludes anyone with a recent tonic-clonic seizure within 24 hours, pregnancy, implanted metal or electronic devices such as a pacemaker or vagal nerve stimulator, and any condition that would prevent MRI scanning, including claustrophobia.
The study will recruit patients through the neuro-oncology clinic at Barts Health NHS Trust, with treating consultants approaching eligible individuals. Healthy volunteers will come from existing volunteer pools at participating centers and from friends or relatives of patients who independently contact the team.
Filter Exchange Imaging Versus Conventional Contrast MRI
The primary outcome is the difference in inflammatory markers, defined here as blood-brain barrier leakage measured using filter exchange imaging at baseline. Investigators will compare those findings between glioma patients and healthy controls, and between glioma patients with and without epilepsy. The protocol also plans to examine whether the extent of leakage varies with tumor subtype and grade, which could help clarify whether more aggressive pathology is associated with a more disrupted vascular interface.
A direct comparison with conventional contrast-enhanced MRI is built into the study. That comparison is clinically relevant because standard MRI often detects only more obvious breakdown of barrier integrity. Subtle leakage can be missed when imaging depends on conventional contrast patterns alone. If filter exchange imaging proves more sensitive, the technique could improve tumor characterization before surgery or treatment planning and might help distinguish tumors with an epileptogenic phenotype from those that are less likely to trigger seizures.
The design is prospective and observational, using a case-control model rather than an intervention. Enrollment is estimated at 56, with study start projected for January 2027. Primary completion is estimated for January 2029, and full completion for January 2030.
A Small Cohort, but a Mechanistically Focused Question
The sample size is modest, and the study will not answer every question about seizure biology in glioma. It does not test a treatment, and it does not yet establish whether barrier leakage predicts seizure burden, response to antiseizure therapy, or long-term oncologic outcomes. Even so, the protocol is tightly aligned with a mechanistic gap that matters in neuro-oncology: clinicians still lack a clear imaging biomarker that links tumor biology, vascular injury, and epilepsy risk in a way that could be translated into routine practice.
The study also raises an important bedside possibility. If barrier leakage proves higher in the epilepsy cohort, then seizure-prone gliomas may represent a biologically distinct subgroup rather than simply a tumor at an eloquent cortical site. That would support more individualized imaging assessment and could eventually shape how clinicians think about surgical planning, postoperative surveillance, and seizure counseling.
Britta Wandschneider, MD, PhD, is listed as the study contact, and the protocol is sponsored by University College London. Individual participant data will not be shared, and the study is not tied to an FDA-regulated drug or device product.
For now, the central question remains whether advanced MRI can detect a vascular abnormality that maps onto both glioma subtype and epileptogenesis. If it can, the finding would do more than refine imaging; it would connect a tumor’s biology to the circuitry that makes seizures emerge in the first place.